2022 Generic Medicine Vaccines 
STAT
OCTOBER 10, 2023
The state’s biotech scene exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drug development and bet on buzzy technologies such as gene editing and messenger RNA vaccines. But the drumbeat of layoffs in 2022 has only grown louder this year.
pharmaphorum
MARCH 29, 2022
With the rapid onset of the pandemic, the race to develop a viable vaccine quickly became a race to secure access to the developed vaccines. In this article, Ben Hargreaves examines how wealth determined the winners and what is now underway to help lower-income countries gain access to the available vaccines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
JULY 3, 2023
Many millions of people are vaccinated against COVID-19, thanks to a messenger RNA (mRNA) encapsulated within a lipid nanoparticle. India is known as the ‘Pharmacy of the World’, as the generic medicine supplier for over 200 countries, both developed and emerging markets. How poised are you to leverage them?
Quality Matters
MAY 30, 2024
The USP Medicine Supply Map shows that 125 drug products were in shortage at the end of 2023, the highest number in a decade. And shortages are lasting longer than ever, with a 3-year average duration in 2023 compared to 2 years in 2022. drug shortages.
European Pharmaceutical Review
SEPTEMBER 21, 2022
Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Adapted vaccines Comirnaty Original/Omicron BA.1 Adapted vaccines Comirnaty Original/Omicron BA.1 Safety update.
European Pharmaceutical Review
DECEMBER 19, 2022
A generic medicine, Diethyl fumarate Accord (dimethyl fumarate), received a positive opinion for the treatment of multiple sclerosis (MS), a chronic disease affecting the central nervous system. The committee recommended to extend the use of original Spikevax vaccine and Spikevax bivalent Original/Omicron BA.1 COVID-19 update.
European Pharmaceutical Review
NOVEMBER 14, 2022
Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine. Read highlights from the CHMP’s September 2022 meeting. COVID-19 update.
Expert insights. Personalized for you.
333 
Let's personalize your content